Cover Image
市場調查報告書

大型製藥公司預測

2015 Big Pharma Outlook

出版商 Datamonitor Healthcare 商品編碼 342057
出版日期 內容資訊 英文 72 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
大型製藥公司預測 2015 Big Pharma Outlook
出版日期: 2015年07月15日 內容資訊: 英文 72 Pages
簡介

大型製藥公司,由於有強力的開發組合、高潛在能力的開發平台資產、尖銳性的高成長市場,預計將成長。

本報告提供大型製藥公司預測調查分析、策略的推動因素、收益趨勢、治療領域等系統性資訊。

調查概要

分析師預測

收益分析

  • 全球收益概要
  • 企業的收益概要
  • 2024年前30名產品
  • 大型製藥公司的開發平台(管線)概要
  • 前30名開發中產品
  • 企業的開發組合
  • 5年的開發分析
  • 到期收益概要
  • 參考文獻

治療領域分析

  • 全球概要
  • 治療領域排行榜
  • 腫瘤學
  • 內分泌疾病、代謝異常、遺傳性疾病
  • 中樞神經系統
  • 參考文獻

策略分析

  • 大型製藥公司的戰略性應用
  • 成為對象的交易
  • 降低成本計劃
  • 大型製藥公司的市場影響
  • 參考文獻

附錄

圖表

目錄
Product Code: DMKC0141800

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies' sharpened focus on highperforming markets. This report explores and visualizes market dynamics in the Big Pharma peer set out to 2024, using in-house sales forecasts. By delving deeper into drivers of strategy, revenue trends, and therapy area focus, this analysis is vital to understanding how the industry will navigate headwinds in order to steer towards robust growth.

What's included in this report:

  • Analyst Outlook
  • Revenue Analysis
  • Therapy Area Analysis
  • Lifecycle Analysis
  • Strategy Analysis

Key questions answered:

  • What are the significant challenges and drivers facing Big Pharma out to 2024?
  • Which companies will propel revenue growth over the forecasts period?
  • Which companies will have leading market share gains and market share losses?
  • How are late stage pipelines positioned, and what are the most-coveted launch products?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Big Pharma based on the lifecycle of products?
  • How is Big Pharma adopting lifecycle management strategies to increase value?

Table of Contents

ABOUT THIS REPORT

  • Analysis structure
  • Key questions answered
  • Highlights

ANALYST OUTLOOK

REVENUE ANALYSIS

  • Global revenue overview
  • Company revenue overview
  • Top 30 products in 2024
  • Big Pharma pipeline overview
  • Top 30 pipeline products
  • Company launch portfolios
  • Five-year launch analysis
  • Expiry revenue overview
  • Bibliography

THERAPY AREA ANALYSIS

  • Worldwide overview
  • Therapy area ranking
  • Oncology
  • Endocrine, metabolic, and genetic disorders
  • Central nervous system
  • Bibliography

LIFECYCLE ANALYSIS

  • Lifecycle management case studies
  • Biosimilars
  • Bibliography

STRATEGY ANALYSIS

  • How has Big Pharma adapted strategically to internal and external headwinds?
  • Targeted deal-making
  • Cost-cutting programs
  • Big Pharma emerging market presence
  • Bibliography

APPENDIX

  • Webinars
  • Forecast methodology

LIST OF FIGURES

  • Figure 1: Big Pharma's prescription pharmaceutical performance, by sales ($m) and growth rate (%), 2011-24
  • Figure 2: Big Pharma ranking, 2007-24
  • Figure 3: Big Pharma waterfall ($m), 2014-24
  • Figure 4: Big Pharma's pipeline overview ranking in 2015
  • Figure 5: Big Pharma's risk-of-expiry sales, by expiry year ($m), 2014-22
  • Figure 6: Big Pharma therapy area sales ($bn), 2008-24
  • Figure 7: Therapy area ranking, 2007-24
  • Figure 8: Big Pharma oncology sales ($bn) and product growth drivers and resistors
  • Figure 9: Oncology waterfall overview, 2014-24
  • Figure 10: Oncology sales growth contribution market share, 2014-24
  • Figure 11: PD-1 and PD-L1 sales forecasts ($m), 2014-24
  • Figure 12: Big Pharma EM&GD sales ($bn) and product growth drivers and resistors, 2011-24
  • Figure 13: EM&GD waterfall overview ($m), 2014-24
  • Figure 14: EM&GD sales growth contribution market share, 2014-24
  • Figure 15: Big Pharma CNS sales ($bn) and product growth drivers and resistors
  • Figure 16: CNS waterfall overview, 2014-24
  • Figure 17: CNS sales growth contribution market share, 2014-24
  • Figure 18: Big Pharma lifecycle management, 2014-24
  • Figure 19: Big Pharma lifecycle portfolio weightings ($m), 2014-24
  • Figure 20: Big Pharma R&D spend ($bn), 2008-24
  • Figure 21: Datamonitor Healthcare's methodology

LIST OF TABLES

  • Table 1: Big Pharma peer set market share analysis
  • Table 2: Big Pharma sales, by company ($bn), 2014-24
  • Table 3: Big Pharma's top 30 products ($m), 2014-24
  • Table 4: Top 30 Big Pharma pipeline sales, by brand ($m), 2014-24
  • Table 5: Big Pharma launch portfolio sales, by company ($m), 2014-24
  • Table 6: Big Pharma product launch, by brand ($m), 2010-19
  • Table 7: Big Pharma's risk-of-expiry sales, by expiry year ($m), 2014-24
  • Table 8: Big Pharma sales by therapy area ($bn), 2014-24
  • Table 9: Big Pharma biosimilar sales ($m), 2015-24
Back to Top